Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +37.87%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +22.25%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.41%
#8 Songbird Songbird +12.58%
#9 Glidr Glidr +11.83%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.69%
Coin of the day
Helium Helium
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Pozycja w akcjach #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Cena akcji
$9.50
Ostatnia synchronizacja: 2025-01-08
Kapitalizacja rynkowa
$819.52M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Poseida Therapeutics, Inc. (PSTX)

Kategoria

Healthcare
Wskaźnik P/B dla Poseida Therapeutics, Inc. (PSTX)
Wskaźnik P/B na dzień August 2026 TTM: 8.26
Według najnowszych raportów finansowych i ceny akcji Poseida Therapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 8.26. Na koniec 2022 wynosił 2.03.
Historia wskaźnika P/B dla Poseida Therapeutics, Inc. od 2016 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
2026 (TTM) 8.26 182.94%
2023 2.92 43.83%
2022 2.03 -25.05%
2021 2.71 10.84%
2020 2.45 -159.95%
2019 -4.08 -43.25%
2018 -7.19 -60.46%
2017 -18.18 -132.79%
2016 55.46 0.00%
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -23.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -24.46%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -69.67%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -55.11%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH